Nektar Therapeutics stock rallied following announcements on February 10-11, 2026. The company released positive results from the 36-week blinded maintenance period of its 52-week REZOLVE-AD Phase 2b study of rezpegaldesleukin, an experimental treatment for moderate-to-severe atopic dermatitis. The study enrolled 393 patients and showed that 71% and 83% of patients maintained EASI-75 responses with monthly and quarterly dosing respectively. The drug also demonstrated up to a 5-fold increase in EASI-100 response rates and a favorable safety profile. Additionally, Nektar announced the pricing of an upsized $400 million public offering of common stock and pre-funded warrants. The stock reached a 52-week high of $66.97, and HC Wainwright & Co. raised its price target to $165 while maintaining a Buy rating.
Read full analysisNektar Therapeutics stock rallied following announcements on February 10-11, 2026. The company released positive results from the 36-week blinded maintenance period of its 52-week REZOLVE-AD Phase 2b study of rezpegaldesleukin, an experimental treatment for moderate-to-severe atopic dermatitis. The study enrolled 393 patients and showed that 71% and 83% of patients maintained EASI-75 responses with monthly and quarterly dosing respectively. The drug also demonstrated up to a 5-fold increase in EASI-100 response rates and a favorable safety profile. Additionally, Nektar announced the pricing of an upsized $400 million public offering of common stock and pre-funded warrants. The stock reached a 52-week high of $66.97, and HC Wainwright & Co. raised its price target to $165 while maintaining a Buy rating.
Nektar Therapeutics is a clinical-stage biotech developing immunology therapies, with its lead candidate rezpegaldesleukin targeting atopic dermatitis (eczema) through a novel regulatory T-cell mechanism. The company is currently advancing toward Phase 3 trials after strong Phase 2b results, positioning rezpeg as a potential competitor to established biologics like Dupixent in the multibillion-dollar eczema market.